Developing novel anthelmintics from plant cysteine proteinases
Jerzy M Behnke1, David J Buttle, Gillian Stepek
1School of Biology, University of Nottingham, University Park, Nottingham, NG7 2RD, UK. jerzy.behnke@nottingham.ac.uk.
Parasites & Vectors
|September 3, 2008
Summary
Drug resistance in livestock and human helminths necessitates new anthelmintics. This review explores cysteine proteinases from plants as potential novel treatments, addressing challenges in their development and market introduction.
Area of Science:
- Parasitology
- Natural Product Chemistry
- Drug Discovery
Background:
- Intestinal helminth infections pose significant threats to livestock and human health.
- Existing synthetic anthelmintics face widespread resistance in livestock nematodes and emerging unresponsiveness in human hookworms.
- The development pipeline for novel synthetic anthelmintics is slow, with no new modes of action expected soon.
Purpose of the Study:
- To review the potential of cysteine proteinases from fruits and plant latices as novel anthelmintic agents.
- To discuss the challenges associated with translating laboratory findings and traditional medicine knowledge into marketable products.
- To highlight the untapped potential of natural compounds for combating helminth infections.
Main Methods:
- Literature review of current research on cysteine proteinases as anthelmintics.
- Analysis of challenges in the development and commercialization of natural product-derived medicines.
- Exploration of traditional and folk medicine knowledge related to plant-based anthelmintics.
Main Results:
- Cysteine proteinases show promise as a new class of anthelmintics.
- Significant hurdles exist in developing natural products, including standardization, efficacy, and safety.
- Folk medicine and laboratory research indicate a rich source of undiscovered anthelmintic compounds in nature.
Conclusions:
- Plant-derived cysteine proteinases represent a promising avenue for novel anthelmintic drug development.
- Overcoming developmental and regulatory challenges is crucial for realizing the therapeutic potential of these natural compounds.
- Further research and investment are needed to harness the vast potential of natural products for human and veterinary medicine.
More Related Videos
Related Concept Videos
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


